and Drug Administration panel Tuesday unanimously recommended the agency approve prasugrel, a proposed anticlotting drug being developed by Eli Lilly and Co. (LLY) and Daiichi Sankyo Co. (4568. TO) , with warnings about bleeding risks. Prasugrel is...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to FDA Panel Recommends Approval Of Lilly's Prasugrel
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account
account